Five Clinical Conundrums in the Management of Giant Cell Arteritis

Rheumatic Disease Clinics of North America

Volumn 33, Issue 4, 2007, Pages 819-834

  Cid, Maria C ^a   García Martínez, Ana ^a   Lozano, Ester ^a   Espígol Frigolé, Georgina ^a   Hernández Rodríguez, José ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; GLUCOCORTICOID; IMATINIB; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE;

ABDOMINAL AORTA ANEURYSM; ANEURYSM; AORTA ANEURYSM; ARTERY OCCLUSION; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG DOSE TITRATION; FRACTURE; GIANT CELL ARTERITIS; HUMAN; IATROGENIC DISEASE; INFECTION; LOW DRUG DOSE; MAMMARY ARTERY; PRIORITY JOURNAL; REVIEW; STEROID THERAPY; VISUAL IMPAIRMENT;

ABORTIFACIENT AGENTS, NONSTEROIDAL; AORTA; AORTOGRAPHY; AZATHIOPRINE; DILATATION, PATHOLOGIC; GIANT CELL ARTERITIS; GLUCOCORTICOIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; METHOTREXATE; PREDNISONE; PULSE THERAPY, DRUG; TOMOGRAPHY, SPIRAL COMPUTED; VISION DISORDERS;

EID: 36249005972     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2007.08.001     Document Type: Review

References (80)

1. Ellis M.E., and Ralston S. The ESR in the diagnosis and management of the polymyalgia rheumatica/giant cell arteritis syndrome. Ann Rheum Dis 42 (1983) 168-170
2. Hoffman G.S., Cid M.C., Hellmann D.B., et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 46 (2002) 1309-1318
3. Hoffman G.S., Cid M.C., Rendt-Zagar K.E., et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis. Ann Intern Med 146 (2007) 621-630
4. Save-Soderbergh J., Malmvall B.E., Andersson R., et al. Giant-cell arteritis as a cause of death. JAMA 255 (1986) 493-496
5. Nuenninghoff D.M., Hunder G.G., Christianson T.J.H., et al. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 48 (2003) 3532-3537
6. Uddhamar D., Eriksson A.L., Nystrom L., et al. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in Northern Sweden. J Rheumatol 29 (2002) 737-742
7. Nordborg E., and Bengtsson B.A. Death rates and causes of death in 284 consecutive patients with giant cell arteritis confirmed by biopsy. Br Med J 299 (1989) 549-550
8. Matteson E.L., Gold K.N., Bloch D.A., et al. Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort. Am J Med 100 (1996) 193-196
9. Salvarani C., Crowson C.S., O'Fallon W.M., et al. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota over a fifty year period. Arthritis Rheum 51 (2004) 264-268
10. Hellmann D., Uhlfelder M., Stone J.H., et al. Domains of quality of life important to patients with giant cell arteritis. Arthritis Rheum 49 (2003) 819-825
11. Cid M.C., Font C., Oristrell J., et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 41 (1998) 26-32
12. González-Gay M.A., García-Porrua C., Llorca J., et al. Visual manifestations of giant cell arteritis: trends and clinical spectrum in 161 patients. Medicine (Baltimore) 79 (2000) 283-292
13. Nesher G., Berkun Y., Mates M., et al. Risk factors for cranial ischemic complications in giant-cell arteritis. Medicine (Baltimore) 83 (2004) 114-122
14. Salvarani C., Cimino L., Machioni P., et al. Risk factors for visual loss in an Italian population-based cohort of patients with GCA. Arthritis Rheum 53 (2005) 293-297
15. Foroozan R., Deramo V.A., Buono L.M., et al. Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology 110 (2003) 539-542
16. Danesh-Meyer H., Savino P.J., and Gamble G.C. Poor visual outcome after visual loss from giant cell arteritis. Ophthalmology 112 (2005) 1098-1103
17. Hayreh S.S., Zimmerman B., Kardon R.H., et al. Visual improvement with glucocorticoid therapy in giant-cell arteritis: report of a large study and review of literature. Acta Ophthalmol Scand 80 (2002) 353-367
18. Hayreh S.S., and Zimmerman B. Visual deterioration in giant cell arteritis patients while on high doses of glucocorticoid therapy. Ophthalmology 110 (2003) 1204-1215
19. Aiello P.D., Trautmann J.C., McPhee T.J., et al. Visual prognosis in giant cell arteritis. Ophthalmology 100 (1993) 550-555
20. Liu G.T., Glaser J.S., Schatz N.J., et al. Visual morbidity in giant cell arteritis: clinical characteristics and prognosis for vision. Ophthalmology 101 (1994) 1779-1785
21. Nuenninghoff D.M., Hunder G.G., Christianson T.J.H., et al. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 48 (2003) 3522-3531
22. Bongartz T., and Matteson E.L. Large-vessel involvement in giant cell arteritis. Curr Opin Rheumatol 18 (2006) 10-17
23. Klein R.G., Hunder G.G., Stanson A.W., et al. Large artery involvement in giant-cell (temporal) arteritis. Ann Intern Med 83 (1975) 806-812
24. Wilke W.S., and Hoffman G.S. Treatment of glucocorticoid-resistant giant cell arteritis. Rheum Clin Dis North Am 21 (1995) 59-71
25. Andersson R., Malmvall B.E., and Bengtsson B.A. Long-term glucocorticoid treatment in giant-cell arteritis. Acta Med Scand 220 (1986) 465-469
26. Hollenhorst R.W., Brown J.R., Wagener H.P., et al. Neurologic aspects of temporal arteritis. Neurology 10 (1960) 490-498
27. Hunder G.G. The early history of giant cell arteritis and polymyalgia rheuamatica: first descriptions to 1970. Mayo Clin Proc 81 8 (2006) 1071-1083
28. Font C., Cid M.C., Coll-Vinent B., et al. Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis. Br J Rheumatol 36 (1997) 251-254
29. Hernández-Rodríguez J., Font C., García-Martínez A., et al. Development of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica: study of a series of 100 patients. Medicine (Baltimore) 86 (2007) 233-241
30. Nesher G., Berkun Y., Mates M., et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 50 (2004) 1332-1337
31. Lee M.S., Smith S.D., Galor A., et al. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 54 (2006) 3306-3309
32. Evans J.M., O'Fallon W.M., and Hunder G.G. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. Ann Intern Med 122 (1995) 502-507
33. González-Gay M.A., García-Porrua C., Piñeiro A., et al. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain. Medicine (Baltimore) 83 (2004) 335-341
34. García-Martínez A., Hernández-Rodríguez J., and Arguis P. Development of aortic aneurysm/dilatation during the follow-up of patients with giant cell arteritis: a cross-sectional screening of 54 prospectively followed patients. Arthritis Rheum (2008) in press
35. Östberg G. Morphological changes in the large arteries in polymyalgia arteritica. Acta Med Scand 533 Suppl (1972) 133-159
36. 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum 55 (2006) 131-137
37. Hoffman G.S. Large-vessel vasculitis: unresolved issues. Arthritis Rheum 48 (2003) 2406-2414
38. Lie J.T. Aortic and extracranial large vessel giant cell arteritis: a review of 72 cases with histopathologic documentation. Semin Arthritis Rheum 24 (1995) 422-431
39. Both M., Aries P.M., Muller-Hulsbeck S., et al. Balloon angioplasty of arteries of the upper extremities in patients with extracranial giant cell arteritis. Ann Rheum Dis 65 (2006) 1124-1130
40. Lozano E., Segarra M., García-Martínez A., et al. Imatinib mesylate inhibits in vitro and ex vivo biologic responses related to vascular occlusion in giant cell arteritis. Ann Rheum Dis (2007) [Epub ahead of print]
41. Salvarani C., Cantini F., Boiardi L., et al. Polymyalgia rheumatica and giant cell arteritis. N Engl J Med 347 (2002) 261-271
42. Nordborg E., and Nordborg C. Giant-cell arteritis: epidemiological clues to its pathogenesis and update on its treatment. Rheumatology 42 (2003) 413-421
43. Proven A., Gabriel S., Orces C., et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 49 (2003) 703-708
44. Delecoeuillerie G., Joly P., Cohen de Lara A., et al. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different glucocorticoid regimens (11 year survey of 210 patients). Ann Rheum Dis 47 (1988) 733-739
45. Hunder G.G., Sheps S.G., Allen G.L., et al. Daily and alternate-day glucocorticoid regimen in maintenance therapy of giant cell arteritis: comparison in a prospective study. Ann Intern Med 82 (1975) 613-618
46. Bengtsson B.A., and Malmvall B.E. An alternate-day glucocorticoid regimen in maintenance therapy of giant cell arteritis. Acta Med Scand 209 (1981) 347-350
47. Jover J.A., Hernández-García C., Morado I.C., et al. Combined treatment of giant cell arteritis with methotrexate and prednisone. Ann Intern Med 134 (2001) 106-114
48. Horton B.T., Magath T.B., and Brown G.E. An undescribed form of arteritis of the temporal vessels. Mayo Clin Proc 7 (1932) 700-701
49. Lie J.T., Brown Jr. A.L., and Carter E.T. Spectrum of aging changes in temporal arteritis: its significance in interpretation of biopsy of temporal artery. Arch Pathol 90 (1970) 278-285
50. Hernández-Rodríguez J., García-Martínez A., Espígol-Frigolé G., et al. Sustained spontaneous clinical remission in giant cell arteritis: report of two cases with long-term follow-up. Arthritis Rheum 55 (2006) 160-162
51. Nesher G., Sonnenblick M., and Friendlander Y. Analysis of steroid-related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol 21 (1994) 1283-1286
52. Queralt C., Hernández-Rodríguez J., García-Martínez A., et al. Baseline osteopenia is associated with subsequent bone loss and fracture in glucocorticoid-treated patients with giant cell arteritis receiving calcium and vitamin D supplements. Arthritis Rheum 93 Suppl (2000) S1793
53. Uzu T., Harada T., Sakaguchi M., et al. Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases. Nephron Clin Pract 105 (2007) C54-C57
54. Spiera R.F., Mitnick H.J., Kupersmith M., et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 19 (2001) 495-501
55. Mahr A., Jover J.A., Spiera R.F., et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 56 (2007) 2789-2797
56. Mazlumzadeh M., Hunder G.G., Easley K.A., et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized, prospective clinical trial. Arthritis Rheum 54 (2006) 3310-3318
57. Salvarani C., Macchioni P., Manzini C., et al. Infliximab plus prednisone or placebo plus prednisone in the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med 146 (2007) 631-639
58. De Silva M., and Hazleman B.L. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 45 (1986) 136-138
59. García-Martínez A., Hernández-Rodríguez J., Grau J.M., et al. Treatment with statins does not exhibit a clinically relevant glucocorticoid-sparing effect in patients with giant cell arteritis. Arthritis Rheum 51 (2004) 674-678
60. Narváez J., Bernad B., Nolla J.M., et al. Statin therapy does not seem to benefit giant cell arteritis. Semin Arthritis Rheum 36 (2007) 322-327
61. Cid M.C., Monteagudo J., Oristrell J., et al. Von Willebrand factor in the outcome of temporal arteritis. Ann Rheum Dis 55 (1996) 927-930
62. Weyand C.M., Fulbright J.W., Hunder G.G., et al. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 43 (2000) 1041-1048
63. Weyand C.M., Hicok K.C., Hunder G.G., et al. Tissue cytokine pattern in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 121 (1994) 484-491
64. García-Martínez A., Hernández-Rodríguez J., Segarra M., et al. Clinical relevance of persistently elevated circulating cytokines (TNFα and IL-6) in the long-term follow-up of patients with giant cell arteritis (GCA). Arthritis Rheum 54 Suppl (2006) S763
65. Rodríguez-Pla A., Bosch-Gil J.A., Rosselló-Urgell J., et al. Metalloproteinase-2 and -9 in giant cell arteritis: involvement in vascular remodeling. Circulation 112 (2005) 264-269
66. Segarra M., García-Martínez A., Sánchez M., et al. Gelatinase expression and proteolytic activity in giant cell arteritis. Ann Rheum Dis 66 (2007) 1429-1435
67. Cid M.C., Cebrián M., Font C., et al. Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis: inflammation-induced angiogenesis as the preferential site of leukocyte-endothelial cell interactions. Arthritis Rheum 43 (2000) 184-194
68. Weyand C.M., Tetzlaff N., Björnsson J., et al. Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum 40 (1997) 19-26
69. Hernández-Rodríguez J., Segarra M., Vilardell C., et al. Elevated production of IL-6 is associated with a lower incidence of disease-related ischemic events in patients with giant cell arteritis: angiogenic activity of IL-6 as a potential protective mechanism. Circulation 107 (2003) 2428-2434
70. Hernández-Rodríguez J., Segarra M., Vilardell C., et al. Tissue production of proinflammatory cytokines (IL-1β, TNFα, and IL-6) correlates with the intensity of the systemic inflammatory response and with glucocorticoid requirements in giant cell arteritis. Rheumatology 43 (2004) 294-301
71. Cid M.C., Hoffman M.P., Hernández-Rodríguez J., et al. Genes related to the maintenance of inflammatory lesions in giant cell arteritis: association between increased CCL2 (MCP-1) expression and persistence of disease activity. Rheumatology 45 (2006) 1356-1363
72. Cid M.C., Campo E., Ercilla M.G., et al. Immunohistochemical analysis of lymphoid and macrophage cell subsets and their immunological activation markers in temporal arteritis: influence of glucocorticoid treatment. Arthritis Rheum 32 (1989) 884-893
73. Brack A., Rittner H.L., Younge B.R., et al. Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-SCID chimeras. J Clin Invest 99 (1997) 2842-2850
74. Weyand C.M., Kaiser M., Yang H., Younge B., et al. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum 46 (2002) 457-466
75. Feldman M., and Maini R.N. Anti-TNF alpha therapy of rheumatoid arthritis: have we learned?. Ann Rev Immunol 19 (2001) 163-196
76. Ma-Krupa W., Jeon M.S., Spoerl S., et al. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med 199 (2004) 173-183
77. Spiera R., and Spiera H. Therapy for giant cell arteritis: can we do better?. Arthritis Rheum 54 (2006) 3071-3074
78. Luqmani R. Treatment of polymyalgia rheumatica and giant cell arteritis: are we any further forward?. Ann Intern Med 146 (2007) 674-676
79. Stahn C., Löwenberg H., Hommes D.W., et al. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol (2007) [Epub ahead of print]
80. Buttgereit F., Burmester G.R., and Lipworth B.J. Optimised glucocorticoid therapy: the sharpening of an old spear. Lancet 365 (2005) 801-803